Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Lymphoma 5Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Mantle-Cell 2Leukemia, Prolymphocytic 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Rituximab 45Cyclophosphamide 38ibrutinib 22fludarabine 22acalabrutinib 21venetoclax 20zanubrutinib 17Lenalidomide 17Bendamustine Hydrochloride 17obinutuzumab 16fludarabine phosphate 14Magnetic Resonance Spectroscopy 14Cytarabine 14Specimen Handling 13CT-P10 13pirtobrutinib 12Biopsy 12glofitamab 10Etoposide 10Whole-Body Irradiation 9Vincristine 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Melphalan 7Doxorubicin 7brexucabtagene autoleucel 6Cyclosporine 6orelabrutinib 5Methotrexate 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × tafasitamab × 1 year × Clear all
NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center

Phase 1 Not yet recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06029309 2025-10-06

ZANU-TAFA

University of Miami

Phase 1/2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡